drugset / Trial / NCT02487017

DC-CIK Combined With TACE in the Treatment of Hepatocellular Carcinoma

NCT02487017

RandomizedParallel-groupOpen-labelTreatment

Summary

Evaluation of DC-CIK cells combined TACE treatment for HCC

Timeline

Start
2015-05
Primary completion
2018-12
Completion
2018-12

Drugs

EvaluationDrugModalityDoseRoute
Subject DC-CIK Cell therapy 8e+09 cells Intravenous